Molecular Analysis for Therapy Choice (MATCH)

Investigator: Eric Bernicker, MD

Study Coordinator: Toniva Boone

Status: Enrolling Number: NCT02465060

Phone: 713.441.0686

IRB Number: Pro00015263


This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
More to Explore